Literature DB >> 10701700

Plasma protein binding of celecoxib in mice, rat, rabbit, dog and human.

S K Paulson1, T A Kaprak, C J Gresk, D M Fast, M T Baratta, E G Burton, A P Breau, A Karim.   

Abstract

The plasma protein binding of celecoxib was determined for animals and humans using in vitro and ex vivo methods. Eight, healthy, human volunteers (three male, five female, 20-39 years) received celecoxib (600 mg) BID for 7 days, blood samples were collected and concentrations of bound and unbound celecoxib determined. The fraction of bound drug in the volunteers was constant (97.4 +/- 0.1%) at total celecoxib plasma concentrations ranging from 0.01 to 4.02 microg/mL. The ex vivo plasma protein binding of celecoxib in the animals was concentration-independent up to approximately 12, 8 and 10 microg/mL for mouse, rat and dog, respectively. The plasma protein binding of celecoxib after a single oral dose of 10 and 300 mg/kg to mice was 98.3 +/- 0.2%, of 1 and 400 mg/kg to rats was 98.3 +/- 0.2% and of 1 and 100 mg/kg to dogs was 98.5 +/- 0.1%. The percent binding of celecoxib to plasma proteins in vitro was slightly lower than those values determined ex vivo. The in vitro binding of celecoxib to plasma protein was constant over the concentrations of 0.1-10 microg/mL for all species, except rat.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10701700     DOI: 10.1002/(sici)1099-081x(199909)20:6<293::aid-bdd188>3.0.co;2-x

Source DB:  PubMed          Journal:  Biopharm Drug Dispos        ISSN: 0142-2782            Impact factor:   1.627


  18 in total

1.  Determination of epinephrine in pharmaceutical formulation by an optimized novel luminescence method using CdS quantum dots as sensitizer.

Authors:  Seyed Naser Azizi; Mohammad Javad Chaichi; Parmis Shakeri; Ahmadreza Bekhradnia
Journal:  J Fluoresc       Date:  2012-10-11       Impact factor: 2.217

Review 2.  Celecoxib: a review of its use in osteoarthritis, rheumatoid arthritis and acute pain.

Authors:  D Clemett; K L Goa
Journal:  Drugs       Date:  2000-04       Impact factor: 9.546

3.  Integration analysis of metabolites and single nucleotide polymorphisms improves the prediction of drug response of celecoxib.

Authors:  Xiaoqing Xing; Pengcheng Ma; Qing Huang; Xiemin Qi; Bingjie Zou; Jun Wei; Lei Tao; Lingjun Li; Guohua Zhou; Qinxin Song
Journal:  Metabolomics       Date:  2020-03-14       Impact factor: 4.290

4.  Control of pulmonary metastases of rat mammary cancer by inhibition of uPA and COX-2, singly and in combination.

Authors:  Douglas M Evans; Kimberly D Sloan Stakleff
Journal:  Clin Exp Metastasis       Date:  2004       Impact factor: 5.150

5.  Influence of age and cytochrome P450 2C9 genotype on the steady-state disposition of diclofenac and celecoxib.

Authors:  Stefanie S Brenner; Charlotte Herrlinger; Karin Dilger; Thomas E Mürdter; Ute Hofmann; Claudia Marx; Ulrich Klotz
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

Review 6.  Limitations of drug concentrations used in cell culture studies for understanding clinical responses of NSAIDs.

Authors:  Garry G Graham; Kieran F Scott
Journal:  Inflammopharmacology       Date:  2021-09-12       Impact factor: 4.473

7.  Development of stealth liposomal formulation of celecoxib: In vitro and in vivo evaluation.

Authors:  M Yasmin Begum; Riyaz Ali M Osmani; Ali Alqahtani; Mohammed Ghazwani; Umme Hani; Hissana Ather; Akhtar Atiya; Mohamed Rahamathulla; Ayesha Siddiqua
Journal:  PLoS One       Date:  2022-04-26       Impact factor: 3.752

8.  Cellular membranes function as a storage compartment for celecoxib.

Authors:  Thorsten J Maier; Susanne Schiffmann; Ivonne Wobst; Kerstin Birod; Carlo Angioni; Marika Hoffmann; Jakob J Lopez; Clemens Glaubitz; Dieter Steinhilber; Gerd Geisslinger; Sabine Grösch
Journal:  J Mol Med (Berl)       Date:  2009-07-30       Impact factor: 4.599

9.  Celecoxib is a CYP1A2 inhibitor in vitro but not in vivo.

Authors:  Marjo J Karjalainen; Pertti J Neuvonen; Janne T Backman
Journal:  Eur J Clin Pharmacol       Date:  2008-01-16       Impact factor: 2.953

10.  Physiologically based pharmacokinetic (PBPK) modeling for prediction of celecoxib pharmacokinetics according to CYP2C9 genetic polymorphism.

Authors:  Young-Hoon Kim; Pureum Kang; Chang-Keun Cho; Eui Hyun Jung; Hye-Jeong Park; Yun Jeong Lee; Jung-Woo Bae; Choon-Gon Jang; Seok-Yong Lee
Journal:  Arch Pharm Res       Date:  2021-07-25       Impact factor: 4.946

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.